IONS 241220 40.00C (IONS241220C40000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

IONS241220C40000

Watchlist

0.20
-0.15-42.86%

15min DelayClose Dec 3 16:00 ET

0.30High0.20Low

Intraday

5D
Daily

News

Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $61
Moomoo NewsDec 2 09:31 ET · Ratings
Express News | Ionis Pharmaceuticals Inc : Raymond James Adds Stock to Its Analyst Current Favorites List
ReutersDec 2 07:43 ET
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $51
Moomoo NewsNov 28 07:31 ET · Ratings
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)
TipRanksNov 28 07:10 ET · Ratings
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Nov 27 11:15 ET
Praxis Precision Medicines to Showcase Updates From Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
GlobeNewswireNov 26 08:00 ET

Comments

Jaguar8

Apr 7 23:52

$Ionis Pharmaceuticals (IONS.US)$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”

Moomoo AI

Mar 17 10:16

Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.

Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?

Moomoo AI

Feb 29 08:12

Kyle Jenne's appointment, with his vast experience and previous tenure at Ionis, is expected to boost the company's commercial organization during a key growth period and product launches. His leadership is anticipated to help Ionis maximize the potential of its innovative medicines to reach patients and healthcare providers.

Press Release: Ionis Announces New Chief Global Product Strategy Officer to Lead Next Phase of Commercial Growth

Moomoo AI

Feb 19 13:10

Recent insider selling at Ionis Pharmaceuticals may indicate insiders believe shares are overpriced. The absence of insider buying and history of sales could caution potential investors.

Insider Sellers Might Regret Selling Ionis Pharmaceuticals Shares at a Lower Price Than Current Market Value

Moomoo AI

Dec 29, 2023 02:22

Investors might be overlooking potential risks as Ionis boasts a similar P/S ratio to the Biotech industry, despite weaker revenue outlook. Modest revenue growth could potentially put a downward pressure on the stock and put investments at risk.

Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now